VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of November 5, 2026, VRTX stock price declined to $548.47 with 1,156,554 million shares trading.

VRTX has a beta of 0.38, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.03 to the broad based SPY ETF.

VRTX has a market cap of $139.02 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.76 earnings per share. This beat revenue expectation by $13 million and exceeded earnings estimates by $.06.

In the last 3 years, VRTX traded as high as $568.67 and as low as $341.90.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

VRTX has outperformed the market in the last year with a price return of +30.1% while the SPY ETF gained +9.9%. VRTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +14.6% and +4.6%, respectively, while the SPY returned -4.5% and -5.0%, respectively.

VRTX support price is $538.12 and resistance is $559.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.